Highlights BioInvent International AB

Equities

BINV

SE0015244520

Market Closed - Nasdaq Stockholm Other stock markets 11:29:33 2024-04-29 am EDT			5-day change	1st Jan Change
25.3 ^SEK	+0.60%		+8.58%	+33.44%

Apr. 24	BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 03	BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	Apr. 03	MT
BioInvent International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
BioInvent International AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
BioInvent International AB Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607	Dec. 05	CI
Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910	Dec. 05	CI
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent	Nov. 03	CI
BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910	23-10-31	CI
BioInvent International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo...	23-10-10
Transgene and BioInvent International AB Announces First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA	23-10-10	CI
Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies	23-09-22	CI
BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors	23-09-08	CI
Bioinvent International AB Achieves Research Milestone Event in Its Exclusive Option and License Agreement with Exelixis, Inc	23-09-07	CI
BioInvent International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
BioInvent International AB Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies	23-06-21	CI
BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023	23-06-13	CI
BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors	23-06-07	CI
BioInvent Ready for Combination Studies with BT-001	23-06-05	CI
BioInvent Wins Regulatory Nod for Proposed Early-stage Study of Cancer Drug	23-06-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioInvent International AB

Equities

BINV

SE0015244520

Highlights

Filters